You’ve been dealing with an injury that feels like it’s healing in slow motion. Maybe you already tried BPC-157 and it helped but didn’t finish the job. Maybe you’re dealing with multiple injury sites — a shoulder and a knee, or lingering inflammation that seems to move around your body. Or maybe your physical therapist mentioned that your tissue isn’t regenerating the way it should.
Then you came across TB-500. The internet says it’s BPC-157’s “complement” — that the two together are the recovery protocol. Forums call it “The Wolverine Stack.” But between the gym-bro testimonials and the vendor sites with buy buttons, you can’t tell what’s real science and what’s marketing dressed up as education.
Here’s the honest picture: TB-500 has a genuinely interesting research profile, including one of the few peptide pharmaceutical development programs (RegeneRx) with actual clinical trials. But most of the evidence is still preclinical. Here’s what we know and what we don’t.
TB-500
Thymosin Beta-4 (synthetic fragment)
Also known as: Tβ4, Thymosin Beta-4, RGN-352
Evidence Summary
- Strongest evidence for:
- Wound healing (42–61% faster re-epithelialization in animal models) and corneal repair (RegeneRx Phase 2 trials for dry eye — strongest human data)
- Promising but early:
- Musculoskeletal recovery (animal data showing muscle fiber regeneration, improved tendon strength) and cardiac repair (2004 Nature study on cardiac progenitor cell activation)
- Mostly anecdotal:
- Neurological protection, hair regrowth
- Key limitation:
- Despite a pharmaceutical development program, large human musculoskeletal RCTs are still missing. Corneal/ophthalmic application has the most clinical trial data.
What It Is
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino-acid protein found in virtually every cell in your body except red blood cells. It’s present in high concentrations in platelets, white blood cells, and wound fluid. It works by binding to actin (a structural protein critical for cell movement), helping cells migrate to injury sites, promoting new blood vessel formation, reducing inflammation, and decreasing scar tissue. If you’ve read our BPC-157 profile, think of TB-500 as its complement — BPC-157 works through growth factor signaling and nitric oxide pathways; TB-500 works through actin regulation and stem cell mobilization. Different angles on tissue repair.
What the Research Says
Wound Healing
T2: Emerging EvidenceFoundational study (Malinda et al., 1999) showed 42% faster re-epithelialization at 4 days and 61% at 7 days in rats, with increased collagen and angiogenesis. Confirmed across healthy, diabetic, and aged animal models.
Corneal Repair
T2: Emerging EvidenceMost clinically advanced application. RegeneRx’s RGN-259 completed multiple clinical trials for dry eye syndrome and corneal wound healing. Phase 2 trials showed significant improvement. Strongest human trial data for any TB-500 application.
Cardiac Repair
T3: Early / Anecdotal2004 Nature study showed Tβ4 promoted cardiac repair after heart attack in mice by activating cardiac progenitor cells and reducing scar tissue. Compelling but needs large human trials.
Musculoskeletal Recovery
T2: Emerging EvidenceAnimal studies show accelerated muscle fiber regeneration, increased satellite cell proliferation, reduced scarring. Strong practitioner consensus but human RCTs are the missing piece.
Neurological
T3: Early / AnecdotalPreclinical neuroprotective effects after TBI and potential in MS models. Very early stage.
It’s worth noting: while TB-500 has human clinical trial data for ophthalmic applications (corneal repair), the musculoskeletal and tissue repair benefits that most consumers seek have not been tested in controlled human trials. The animal data is consistent and the practitioner consensus is strong, but animal data and practitioner consensus are not proof.
Typical Protocol
| Route | Subcutaneous injection |
| Dosage Range | Loading: 2.0–2.5 mg twice weekly for 4–6 weeks. Maintenance: lower frequency, often twice monthly. |
| Frequency | Twice weekly (loading), twice monthly (maintenance) |
| Time to Effect | 2–4 weeks for initial improvements |
| Note | Provider determines protocol based on injury type and goals. |
Protocols vary by individual. Always follow your prescribing provider's instructions.
Risks & Side Effects
- Injection site reactions — mild and the most commonly reported side effect.
- Headache and lightheadedness — transient.
- Angiogenesis concern — TB-500 promotes new blood vessel formation, which theoretically could support tumor growth in someone with active cancer. No studies show TB-500 causes cancer, but people with active malignancies should avoid it.
- Contraindications: active cancer, pregnancy, breastfeeding.
- Banned by WADA. A positive test can end a season or career.
Who Should Not Consider TB-500
If you have an active malignancy or recent cancer history: TB-500 promotes angiogenesis (new blood vessel formation). Theoretically, this could support tumor vascularization. No studies have shown that TB-500 causes cancer, but people with active cancers should avoid this compound. Like BPC-157, this conversation belongs with your oncologist, not your peptide provider.
If you are pregnant or breastfeeding: No safety data exists. Absolute contraindication.
If you are a competitive athlete in a tested league: TB-500 is prohibited by WADA and major equine racing authorities. Provider prescription is not a defense under anti-doping rules.
If you are self-sourcing from unregulated vendors: TB-500 remains Category 2 as of April 2026 despite the announced reclassification. Buying “research peptide” TB-500 from unregulated vendors gives you no assurance of purity, sterility, or accurate dosing.
Legal & Access Status
Category 2 since late 2023. Included in the February 2026 announcement of peptides expected to return to Category 1, but the formal reclassification has not been published. Not PCAC-referred. Until the FDA formally updates the list, TB-500 remains technically not compoundable through 503A pharmacies.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include IGF-1, fasting glucose, CBC, CMP and a thyroid panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Lab recommendations are the same regardless of which service you use. See how we make money.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products. See how we make money.
Questions for Your Provider
- 1For my specific injury, would you recommend TB-500 alone or combined with BPC-157? What’s the rationale?
- 2What loading and maintenance schedule do you recommend?
- 3Given TB-500’s angiogenic properties, is there anything in my health history that makes it inappropriate?
- 4Which compounding pharmacy sources your TB-500, and can they compound it legally right now?
- 5How will we measure progress and what timeline should I expect?
- 6What’s the total cost for a typical loading plus maintenance cycle?
Find a Provider
We’re finalizing our vetted provider list. Subscribe to be notified when provider recommendations go live.
When provider links go live, we’ll disclose all affiliate relationships here. See how we make money.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.